Skip to main content
. 2020 Dec 13;27(1):1729–1740. doi: 10.1080/10717544.2020.1856219

Figure 5.

Figure 5.

Locoregional delivery of AM and ATO on Huh7 HCC subcutaneous model significantly inhibited tumor growth through induction of apoptosis and inhibition of proliferation. The locoregional delivery of AM (2 mg/kg), ATO (2 mg/kg), vacant microsphere (PLGA), or PBS as control (CT) was through intratumoral injection (every three days for 15 days) on Huh7 subcutaneous mice model. (A–C). PLGA did not inhibit tumor growth as indicated in (A) tumor volume, (B) tumor weight at the time of harvest, and (C) representative picture of tumor at the time of harvest (data: mean ± SD; **p<.01). (D–E) Both AM and ATO demonstrated markedly antitumoral effects as indicated in (D) tumor volume, (E) tumor weight at the time of harvest, and (F) representative picture of the tumor at the time of harvest (data: mean ± SD; **p<.01). No difference on tumor volume and weight was noticed between AM and ATO. The effects of AM and ATO on apoptosis and proliferation were evaluated by immunohistochemical stains of (G) caspase-3 and (H) Ki-67 on tumor tissue. Both CT and PLGA showed the same caspase-3 and Ki-67 signal intensity. Compared to CT and PLGA, AM, and ATO significantly induced caspase-3 activity and inhibited Ki-67 expression. No difference between AM and ATO in term of caspase-3 activation and Ki-67 expression. Bar = 100 μm.